<DOC>
	<DOCNO>NCT02658162</DOCNO>
	<brief_summary>Safety efficacy study SANGUINATE reduction delay graft function ( DGF ) patient recipient donation brain death ( DBD ) donor kidney .</brief_summary>
	<brief_title>A Study SANGUINATEâ„¢ Reduction Delayed Graft Function Kidney Transplant Patients</brief_title>
	<detailed_description>Sixty ( 60 ) adult subject recipient donation brain death ( DBD ) donor kidney meet eligibility criterion randomize 1:1 within 48 hour prior transplant surgery receive : two infusion SANGUINATE dose 320 mg/kg placebo day surgery approximately 24 hour surgery . Patients hospitalize 5 day study duration 30 day .</detailed_description>
	<mesh_term>Delayed Graft Function</mesh_term>
	<criteria>1 . Able understand provide write informed consent . 2 . Male female subject least 18 year age . 3 . Dialysisdependent renal failure initiate least 3 month prior transplantation . 4 . Subject recipient first kidney transplant decease donor ( brain death criterion ) . 5 . Is able receive intravenous infusion study drug . 6 . Anticipated donor organ cold ischemia time &lt; 30 hour . 7 . A calculated prediction DGF risk least 25 % . 8 . Females childbearing potential must agree use 2 form effective birth control regimen ( least onebarrier method ) initial 30day study period . 9 . Male subject must agree use condom suitable mean pregnancy prevention . 1 . Has receive blood transfusion pack red blood cell ( PRBC ) , leukocytepoor blood , within 90day period prior screen . 2 . Recipient live donor kidney kidney donation cardiac death ( DCD ) donor . 3 . Recipient donor kidney preserve normothermic machine perfusion . 4 . Is schedule undergo multiorgan transplantation . 5 . Has plan transplant kidney ( ) donor &lt; 6 year age . 6 . Has plan transplant kidney implant en bloc ( dual kidney transplant ) . 7 . Has plan transplant dual kidney ( donor ) transplant en bloc . 8 . Body Mass Index ( BMI ) &gt; 38 kg/m2 9 . Machine perfuse preservation donor kidney . 10 . Is schedule transplantation kidney donor know receive investigational therapy ( another Investigational New Drug ) ischemic/reperfusion injury immediately prior organ recovery . 11 . Is schedule receive blood typeincompatible donor kidney . 12 . Has undergone desensitization remove antibody prior transplantation . 13 . Total bilirubin &gt; 1.5 mg per dL , transaminase twice upper limit normal evidence hepatic insufficiency 14 . Has participate investigational study within last 30 day receive investigational product within 5 halflives study drug administration , whichever long . Potential subject participate strictly observational study study involve approve treatment discuss Medical Monitor . 15 . Has history human immunodeficiency virus ( HIV ) 16 . History presence active substance abuse ( illicit drug alcohol ) previous 6 month , believe Investigator 17 . Presence ECGbased evidence acute myocardial infarction , unstable angina , decompensated heart failure , third degree heart block cardiac arrhythmia associate hemodynamic instability 18 . History presence disease psychiatric condition Investigator 's assessment would increase risk subject associate study participation , drug administration interpretation result 19 . History biopsyconfirmed malignancy within 5 year randomization , exception adequately treat basal cell squamous cell carcinoma situ skin lesion , carcinoma cervix situ , early detect prostate cancer . 20 . Female subject pregnant breast feeding . 21 . Has positive T Bcell crossmatch NIH antiglobulin lymphocytotoxicity method , perform . 22 . Has positive T Bcell crossmatch AND donor specific antihuman leukocyte antigen ( antiHLA ) antibody ( DSA ) detect flow cytometry/Luminex base antigenspecific antiHLA antibody test , perform .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>